|Bid||56.80 x 120000|
|Ask||57.30 x 120000|
|Day's Range||56.12 - 57.18|
|52 Week Range||46.90 - 67.95|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 28, 2023|
|Forward Dividend & Yield||2.00 (3.93%)|
|Ex-Dividend Date||May 02, 2022|
|1y Target Est||N/A|
Bayer investor Deka has called for CEO Werner Baumann to be replaced ahead of his scheduled departure, adding to mounting pressure on the German drugmaker. "Bayer needs a new strategic positioning, which cannot be credibly accomplished under Werner Baumann," Ingo Speich, head of sustainability and corporate governance at Deka, told the Frankfurter Allgemeine Sonntagszeitung (FAS) newspaper in remarks published on Saturday. The mutual funds firm is among Bayer's 20 largest shareholders.
Does Bayer’s C-suite have sufficient chemistry with its shareholders? The recent addition of two activist investors suggests maybe not. Jeff Ubben at Inclusive Capital Partners thinks the current management team is too tight-knit and wants Bayer to hire a new chief executive from outside.
Bayer Aktiengesellschaft (OTC: BAYR.Y) and AstraZeneca (NASDAQ: AZN) are elite healthcare companies with shares that trade for less than $100 and make excellent long-term investments because of their revenue and earnings growth, promising pipelines, and above-average dividends. Bayer was down 11.2% in 2022 and currently trades for about $15 a share while AstraZeneca was up 16.4% in 2022 and currently trades for around $70 a share. Bayer is a huge German life science conglomerate.